Comments

Travere Therapeutics Stock Guidance

TVTXNASDAQ
Logo brought to you by Benzinga Data
Trade with Public
Trade with Public
$34.51
-0.50-1.43%
Last update: Dec 12, 9:27 AM
OverviewNewsEarningsOptions

Guidance

Analyst RatingsInsider TradesShort InterestStock Report

Travere Therapeutics Stock Guidance | NASDAQ:TVTX | Benzinga

Travere Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Get Alert
01/09/2023TVTX
Travere Therapeutics
FY2022———$212.00M$212.00M$212.08MGet Alert
01/10/2022TVTX
Travere Therapeutics
FY2021———$227.00M$227.00M$227.25MGet Alert

FAQ

Q

What is the most recent guidance for Travere Therapeutics (TVTX)?

A

There have been no specific sales or earnings guidance reported for Travere Therapeutics in recent months.

Browse guidance and forecast on all stocks.

People Also Watch

IDEAYA Biosciences Inc
NASDAQ:IDYA
$34.00
1.31%
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
$36.38
0.50%
Ascentage Pharma Group International
NASDAQ:AAPG
$30.35
1.20%
No data available
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
$28.79
-2.31%
Xenon Pharmaceuticals Inc
NASDAQ:XENE
$44.12
1.05%
Kiniksa Pharmaceuticals International PLC
NASDAQ:KNSA
$41.12
0.27%
Olema Pharmaceuticals inc
NASDAQ:OLMA
$32.99
4.45%
Dyne Therapeutics Inc
NASDAQ:DYN
$19.51
0.46%
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved